Current Advances in Continuous Glucose Monitoring Technology
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.
Continous glucose monitors (CGMs), technology designed to improve glycemic control and quality of life for persons with diabetes, received a flurry of FDA appprovals in 2018.
Since then, the FDA-approved CGMs have benefited from a variety of enhanced features, new applications, and new approvals that promise to further advance the management of diabetes and thus the functioning and quality of life of those living with the disease.
Scroll through the slides below for concise summaries of the key original CGM approvals and features and the innovations and advances that have been approved since.
Dexcom G6® for standalone and integration.
Dexcom APIs gain FDA clearance
Eversense®: First long-term implantable system
Next-gen Eversense® CGM System shows promise
FreeStyle® Libre: No fingersticks
Next gen FreeStyle® Libre 2 iCGM
MiniMed® 630G insulin pump system/SmartGuard™
